Natixis’s Celgene Corp CELG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-2,234,713
Closed -$222M 1026
2019
Q3
$222M Buy
2,234,713
+1,400,844
+168% +$133M 1.43% 12
2019
Q2
$77.1M Buy
833,869
+629,327
+308% +$59.8M 0.59% 37
2019
Q1
$19.3M Sell
204,542
-210,245
-51% -$18.4M 0.12% 171
2018
Q4
$26.6M Buy
414,787
+53,359
+15% +$3.94M 0.22% 118
2018
Q3
$32.3M Sell
361,428
-391,601
-52% -$34.6M 0.19% 126
2018
Q2
$59.8M Sell
753,029
-993,387
-57% -$82.5M 0.32% 87
2018
Q1
$156M Buy
1,746,416
+1,241,120
+246% +$119M 0.96% 19
2017
Q4
$52.7M Buy
505,296
+340,074
+206% +$38.4M 0.41% 67
2017
Q3
$24.1M Buy
165,222
+161,530
+4,375% +$22M 0.22% 113
2017
Q2
$479K Sell
3,692
-215,254
-98% -$26.4M 0.01% 529
2017
Q1
$27.2M Sell
218,946
-44,400
-17% -$5.31M 0.34% 79
2016
Q4
$30.5M Buy
+263,346
New +$29.3M 0.31% 82
2016
Q3
Sell
-187,894
Closed -$18.5M 595
2016
Q2
$18.5M Buy
187,894
+131,724
+235% +$13.6M 0.34% 68
2016
Q1
$5.62M Buy
+56,170
New +$5.78M 0.09% 140
2015
Q2
Sell
-4,922
Closed -$567K 478
2015
Q1
$567K Sell
4,922
-13,924
-74% -$1.66M 0.01% 291
2014
Q4
$2.11M Buy
+18,846
New +$1.99M 0.03% 172
2014
Q3
Sell
-257,690
Closed -$22.1M 524
2014
Q2
$22.1M Sell
257,690
-499,480
-66% -$38M 0.27% 90
2014
Q1
$52.9M Buy
757,170
+390,316
+106% +$30.9M 0.69% 33
2013
Q4
$31M Sell
366,854
-248,546
-40% -$19.7M 0.27% 82
2013
Q3
$47.4M Sell
615,400
-104,610
-15% -$7.33M 0.51% 53
2013
Q2
$42.1M Buy
+720,010
New +$43.3M 0.6% 40

Other funds holding CELG

Natixis's CELG Position: Q4 2019 in Review

Natixis sold out of Celgene Corp (CELG) in Q4 2019, closing a stake of 2,234,713 shares — an estimated $222M sold.

Natixis first reported a position in CELG in Q2 2013 and held it in 21 quarters. The position peaked at $222M in Q3 2019. 4 funds tracked by Wall St. Rank hold CELG as of Q4 2019.

  • Natixis reported no remaining Celgene Corp position as of Q4 2019 after selling out during the quarter.
  • Natixis sold 2,234,713 Celgene Corp shares in Q4 2019, an estimated $222M.
  • Natixis first reported a position in Celgene Corp in Q2 2013 and held it in 21 quarters.
  • Natixis's Celgene Corp position peaked at $222M in Q3 2019.
  • 4 funds tracked by Wall St. Rank held Celgene Corp as of Q4 2019.

Based on Natixis's 13F filing for Q4 2019, filed 14 Feb 2020.